Vanguard Group
ZOM

Vanguard Group’s Zomedica Corp. ZOM Stock Holding History

Vanguard Group’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48,078,677
Closed -$5.77M – 4363
2024
Q4 		$5.77M Sell
48,078,677
-248,314
-0.5% -$31.3K ﹤0.01% 3219
2024
Q3 		$6.62M Hold
48,326,991
– – ﹤0.01% 3146
2024
Q2 		$7.07M Hold
48,326,991
– – ﹤0.01% 3096
2024
Q1 		$7.05M Sell
48,326,991
-576,660
-1% -$80.7K ﹤0.01% 3142
2023
Q4 		$9.79M Buy
48,903,651
+95,662
+0.2% +$16.8K ﹤0.01% 2960
2023
Q3 		$8.16M Hold
48,807,989
– – ﹤0.01% 2998
2023
Q2 		$9.76M Sell
48,807,989
-179,586
-0.4% -$36.4K ﹤0.01% 2960
2023
Q1 		$10.4M Buy
48,987,575
+167,305
+0.3% +$41K ﹤0.01% 2915
2022
Q4 		$7.96M Buy
48,820,270
+2,491,265
+5% +$510K ﹤0.01% 3053
2022
Q3 		$9.78M Buy
46,329,005
+2,252,651
+5% +$596K ﹤0.01% 2960
2022
Q2 		$9.7M Buy
44,076,354
+3,469,211
+9% +$883K ﹤0.01% 3003
2022
Q1 		$13.7M Sell
40,607,143
-1,028,539
-2% -$337K ﹤0.01% 2980
2021
Q4 		$12.8M Buy
41,635,682
+181,358
+0.4% +$81.7K ﹤0.01% 3091
2021
Q3 		$21.7M Sell
41,454,324
-1,046,917
-2% -$618K ﹤0.01% 2824
2021
Q2 		$35.4M Buy
42,501,241
+1,725,044
+4% +$1.61M ﹤0.01% 2548
2021
Q1 		$64.4M Buy
40,776,197
+21,435,752
+111% +$35M ﹤0.01% 2171
2020
Q4 		$4.46M Buy
19,340,445
+8,564,290
+79% +$1.09M ﹤0.01% 3416
2020
Q3 		$1.19M Buy
10,776,155
+2,811,810
+35% +$387K ﹤0.01% 3619
2020
Q2 		$1.9M Buy
7,964,345
+7,669,566
+2,602% +$1.46M ﹤0.01% 3442
2020
Q1 		$56K Hold
294,779
– – ﹤0.01% 3995
2019
Q4 		$98K Hold
294,779
– – ﹤0.01% 4009
2019
Q3 		$110K Sell
294,779
-88,375
-23% -$27.4K ﹤0.01% 4031
2019
Q2 		$88K Buy
383,154
+222,920
+139% +$67.6K ﹤0.01% 4063
2019
Q1 		$56K Buy
160,234
+12,259
+8% +$10.8K ﹤0.01% 4056
2018
Q4 		$182K Buy
147,975
+2,228
+2% +$3.53K ﹤0.01% 3917
2018
Q3 		$273K Buy
145,747
+8,381
+6% +$17.9K ﹤0.01% 3959
2018
Q2 		$309K Buy
+137,366
New +$276K ﹤0.01% 3912

Other funds holding ZOM

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
GJIA
Glass Jacobson Investment Advisors Owings Mills, Maryland $290M AUM 17.7% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

Vanguard Group's ZOM Position: Q1 2025 in Review

Vanguard Group sold out of Zomedica Corp. (ZOM) in Q1 2025, closing a stake of 48,078,677 shares — an estimated $5.77M sold.

Vanguard Group first reported a position in ZOM in Q2 2018 and held it in 27 quarters. The position peaked at $64.4M in Q1 2021. 23 funds tracked by Wall St. Rank hold ZOM as of Q1 2025.

  • Vanguard Group reported no remaining Zomedica Corp. position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 48,078,677 Zomedica Corp. shares in Q1 2025, an estimated $5.77M.
  • Vanguard Group first reported a position in Zomedica Corp. in Q2 2018 and held it in 27 quarters.
  • Vanguard Group's Zomedica Corp. position peaked at $64.4M in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.